Ovid Therapeutics IPO

5/5/2017

IPO

$75,000,000

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $35 million to conduct and complete a Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in OV101 in adolescents with Angelman syndrome or Fragile X syndrome, as well as other future Phase 2 trials in adolescents and pediatrics in these indications; approximately $17 million to conduct and complete a Phase 1b/2a trial of OV935 in patients with epileptic encephalopathies; approximately $7 million for other ongoing research and development activities related to additional drug candidates and preclinical programs; and the remainder to fund the expansion of patient-focused activities, including social media outreach and involvement, and for business development, working capital and general corporate purposes.

Publicly-held

Biopharmaceutical

1460 Bdwy.
New York, NY 10036
USA

Ovid Therapeutics Inc. (NASDAQ: OVID) is named for the Roman poet, Publius Ovidius Naso (Ovid), known for his epic work, Metamorphoses or Books of Transformations. Ovid is passionately committed to transforming the lives of patients with rare and orphan diseases of the brain--patients who currently have few if any treatment options or prospects for cure or improvement.